Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia.
Cressman S, Karsan A, Hogge DE, McPherson E, Bolbocean C, Regier DA, Peacock SJ. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br J Haematol. 2016 08; 174(4):526-35.